These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 25061280)

  • 1. New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways.
    Perez SM; Lodge DJ
    Drug Des Devel Ther; 2014; 8():887-96. PubMed ID: 25061280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia.
    Gill KM; Cook JM; Poe MM; Grace AA
    Schizophr Bull; 2014 Mar; 40(2):341-50. PubMed ID: 24464874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia.
    Lodge DJ; Grace AA
    Trends Pharmacol Sci; 2011 Sep; 32(9):507-13. PubMed ID: 21700346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis.
    Sonnenschein SF; Grace A
    Expert Opin Ther Targets; 2021 Jan; 25(1):15-26. PubMed ID: 33170748
    [No Abstract]   [Full Text] [Related]  

  • 5. Hippocampal α5-GABA
    Perez SM; McCoy AM; Prevot TD; Mian MY; Carreno FR; Frazer A; Cook JM; Sibille E; Lodge DJ
    Biol Psychiatry Glob Open Sci; 2023 Jan; 3(1):78-86. PubMed ID: 36712569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention.
    Gomes FV; Grace AA
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia.
    Gill KM; Lodge DJ; Cook JM; Aras S; Grace AA
    Neuropsychopharmacology; 2011 Aug; 36(9):1903-11. PubMed ID: 21562483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A biochemical theory of schizophrenia].
    Kornhuber HH; Kornhuber J; Kim JS; Kornhuber ME
    Nervenarzt; 1984 Nov; 55(11):602-6. PubMed ID: 6151120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamate and dopamine in schizophrenia: an update for the 21st century.
    Howes O; McCutcheon R; Stone J
    J Psychopharmacol; 2015 Feb; 29(2):97-115. PubMed ID: 25586400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neonatal ventral hippocampal lesion model of schizophrenia: effects on dopamine and GABA mRNA markers in the rat midbrain.
    Lipska BK; Lerman DN; Khaing ZZ; Weinberger DR
    Eur J Neurosci; 2003 Dec; 18(11):3097-104. PubMed ID: 14656305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia.
    Uliana DL; Lisboa JRF; Gomes FV; Grace AA
    Biochem Pharmacol; 2024 Oct; 228():116298. PubMed ID: 38782077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depression and schizophrenia viewed from the perspective of amino acidergic neurotransmission: Antipodes of psychiatric disorders.
    Wierońska JM; Pilc A
    Pharmacol Ther; 2019 Jan; 193():75-82. PubMed ID: 30149102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vagal nerve stimulation reverses aberrant dopamine system function in the methylazoxymethanol acetate rodent model of schizophrenia.
    Perez SM; Carreno FR; Frazer A; Lodge DJ
    J Neurosci; 2014 Jul; 34(28):9261-7. PubMed ID: 25009259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment.
    Snyder GL; Vanover KE
    Curr Pharm Des; 2014; 20(31):5093-103. PubMed ID: 24345266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia.
    Sonnenschein SF; Grace AA
    Neuropharmacology; 2020 Feb; 163():107632. PubMed ID: 31077730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PDE Inhibitors for the Treatment of Schizophrenia.
    Snyder GL; Vanover KE
    Adv Neurobiol; 2017; 17():385-409. PubMed ID: 28956340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological perspectives: the role of glutamate in schizophrenia and its treatment.
    Steele D; Moore RL; Swan NA; Grant JS; Keltner NL
    Perspect Psychiatr Care; 2012 Jul; 48(3):125-8. PubMed ID: 22724397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus.
    Huang M; Li Z; Dai J; Shahid M; Wong EH; Meltzer HY
    Neuropsychopharmacology; 2008 Nov; 33(12):2934-45. PubMed ID: 18418367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Genes in Schizophrenia and Their Importance in Choosing the Appropriate Antipsychotic Treatment.
    Werner FM; Coveñas R
    Curr Pharm Des; 2021 Oct; 27(30):3281-3292. PubMed ID: 33588721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Circuitry of Dopamine System Regulation and its Disruption in Schizophrenia: Insights Into Treatment and Prevention.
    Grace AA; Gomes FV
    Schizophr Bull; 2019 Jan; 45(1):148-157. PubMed ID: 29385549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.